medigraphic.com

2021, Number 4

<< Back Next >>

Rev Hematol Mex 2021; 22 (4)

Urological complications in patients with hematologic malignancy

Dorantes-Carrillo LA, Barbosa-Loría DM, Morales-De Azcué M, Labra-Salgado IR, Morales-Adrián JJ

Language: Spanish
References: 30
Page: 246-258
PDF size: 310.86 Kb.


ABSTRACT

Background: Request for medical attention in the emergency department is frequent in patients with hematologic malignancy, because its underlying disease per se corresponds to a sub-optimal status of immunity, hemostasis and thrombosis. In these patients, chemotherapy often causes prolonged periods of deep cytopenia, being this the moment of greater risk of infections and bleeding complications, which contributes as a major cause of mortality among these patients.
Clinical case: A 59-year-old male patient with diagnoses of acute myeloblastic leukemia and nephrolithiasis who throughout his treatment presented hematuria and recurrent urinary tract infections that required joint management of Urology and Hematology services in a tertiary hospital in Mexican southeast.
Conclusions: Urological complications are considered real urgencies in patients with hematologic malignancy and represent a therapeutic challenge primarily due to the lack of joint management guidelines to regulate the proper treatment in these cases, as well the patients that are ineligible for surgery, either by the low functional status and/or impaired hemostasis and thrombosis, caused by hematologic malignancy itself or treatment.


REFERENCES

  1. Molica M, Breccia M, Foa R, Jabbour E, Kadia TM. Maintenancetherapy in AML: The past, the present and thefuture. Am J Hematol 2019; 94 (11): 1254-65. doi: 10.1002/ajh.25620.

  2. Sant M, Allemani C, Tereanu C. Incidence of hematologicmalignancies in Europe by morphologic subtype: Results ofthe HAEMACARE project Blood 2010; 116: (19): 3724-3734.doi: 10.1182/blood-2010-05-282632.

  3. Patel M, Sachan R, Goel A. Frank hematuria as sole manifestationof acute myeloid leukemia: A case report. IntJ Case Reports Images 2013; 4 (10): 575. doi: 10.5348/ijcri-2013-10-383-CR-12

  4. Mirheydar HS, Banapour P, Massoudi R, Palazzi KL, JabajiR, Reid EG, et al. What is the incidence of kidney stonesafter chemotherapy in patients with lymphoproliferativeor myeloproliferative disorders? Int Braz J Urol 2014; 40(6): 772-80. doi: 10.1590/S1677-5538.IBJU.2014.06.08.

  5. İnözü M, Bajin İY, Aydın Z, Aksoy ÖY, Güneş A, Yaralı HN,et al. Macroscopic hematuria in a patient with leukemia:Answers. Pediatr Nephrol 2020; 12-3. https://doi.org/10.1007/s00467-020-04778-y.

  6. Jaing TH, Hung IJ, Lin CJ, Chiu CH, Luo CC, Wang CJ. Acutemyeloid leukemia complicated with staghorn calculus. JpnJ Clin Oncol 2002; 32 (9): 365-7. https://doi.org/10.1093/jjco/hyf077.

  7. Ozyilmaz E, Aydogdu M, Sucak G, Aki SZ, Ozkurt ZN, YeginZA, et al. Risk factors for fungal pulmonary infections inhematopoietic stem cell transplantation recipients: Therole of iron overload. Bone Marrow Transplant 2010; 45(10): 1528-33. https://doi.org/10.1038/bmt.2009.383.

  8. Dindo D, Demartines N, Clavien PA. Classification of surgicalcomplications: A new proposal with evaluation in a cohortof 6336 patients and results of a survey. Ann Surg 2004; 240(2): 205-13. doi: 10.1097/01.sla.0000133083.54934.ae.

  9. Al Kalbani N, Weitzman S, Abdelhaleem M, Carcao M, AblaO. Acute lymphoblastic leukemia presenting with grosshematuria. Paediatr Child Health (Oxford) 2007; 12 (7):573-4. doi: 10.1093/pch/12.7.573.

  10. Nikita-Mehra VR. Tranexamic acid ‑ induced acute renalfailure in a pediatric patient with acute myeloid leukemia :A cautionary note. Cancer Res Stat Treat 2020; 3 (September):3-5. DOI: 10.4103/CRST.CRST_158_20.

  11. Türk C, Petřík A, Sarica K, Seitz C, Skolarikos A, Straub M, etal. EAU Guidelines on Diagnosis and Conservative Managementof Urolithiasis. Eur Urol 2016; 69 (3): 468-74. doi:10.1016/j.eururo.2015.07.040.

  12. Grasa V, Lainez N, Villafranca E. Manejo urgente de las complicacionesurológicas en el paciente tumoral Emergencytreatment of urological complications in cancer patients.An Sist Sanit Navar. 2004; 27 (Supl. 3): 125-35.

  13. Kim SW, Kim SD, Yoo JM, Cho YH, Sohn DW. Urolithiasisin patients suffering from malignant hematologic diseases.Yonsei Med J 2010; 51 (2): 244-7. doi: 10.3349/ymj.2010.51.2.244.

  14. Hori D, Kobayashi R, Suzuki D, Kodama K, Yanagi M,Matsushima S, et al. A survey of hypercalciuria duringchemotherapy in acute lymphoblastic leukemia. Pediatr Int2021; 63 (8): 923-928. doi: 10.1111/ped.14527.

  15. Kaste SC, Thomas NA, Rai SN, Cheon K, et al. Asymptomatickidney stones in long-term survivors of childhood acutelymphoblastic leukemia. Leukemia 2009; 23 (1): 1-7. doi:10.1038/leu.2008.269.

  16. Shiozawa Y, Sakaguchi S, Sakakibara O, Yagishita K,Saito M, Yamashiro Y. Urolithiasis in an acute lymphoblasticleukemia child during induction chemotherapy.Pediatr Hematol Oncol 2008; 25 (4): 359-63. doi:10.1080/08880010802016706.

  17. Córdova-Chavez NA, Onofre-Castillo JJ, Mancilla-SerratoAA, Santana-Vela I, Valdés-Martínez FJ, et al. Utilidad delas unidades Hounsfield en la predicción de la composiciónquímica de los cálculos urinarios. An Radiol Mex 2014;13: 40-4.

  18. Miceli MH, Dong L, Grazziutti ML, Fassas A, Thertulien R,Van Rhee F, et al. Iron overload is a major risk factor forsevere infection after autologous stem cell transplantation:A study of 367 myeloma patients. Bone Marrow Transplant2006; 37 (9): 857-64. doi: 10.1038/sj.bmt.1705340.

  19. Khan FA, Fisher MA, Khakoo RA. Association of hemochromatosiswith infectious diseases: expanding spectrum.Int J Infect Dis 2007; 11 (6): 482-7. doi: 10.1016/j.ijid.2007.04.007.

  20. López M, Alvarez J. Concentraciones de ferritina en pacientescon enfermedades hematológicas transfundidoscon más de tres unidades de glóbulos rojos. Med InternaMex 2011; 27 (1): 17-22.

  21. Zheng B, Toarta C, Cheng W, Taljaard M, Reaume N, Perry JJ.Accuracy of the ultinational Association of Supportive Carein Cancer (MASCC) and Clinical Index of Stable Febrile Neutropenia(CISNE) scores for predicting serious complicationsin adult patients with febrile neutropenia: A systematicreview and meta-analysis. Crit Rev Oncol Hematol 2020;149. doi: 10.1016/j.critrevonc.2020.102922.

  22. World Health Organization. Leukaemia Source: Globocan2018. Int Agency Res Cancer 2019; 1-2. Availablefrom: https://gco.iarc.fr/today/data/factsheets/populations/360-pakistan-fact-sheets.pdf.

  23. The Global Cancer Observatory. Mexico 2018. World HealOrgan 2020; 283: 1-2.

  24. Huls G, Chitu DA, Havelange V, Jongen-Lavrencic M, VanDe Loosdrecht AA, Biemond BJ, et al. Azacitidine maintenanceafter intensive chemotherapy improves DFS in olderAML patients. Blood 2019; 133 (13): 1457-64. https://doi.org/10.1182/blood-2018-10-879866.

  25. Assimos D, Krambeck A, Miller NL, Monga M, MuradMH, Nelson CP, et al. Surgical management of stones:American Urological Association/Endourological SocietyGuideline, PART I. J Urol 2016; 196 (4): 1153-60. http://dx.doi.org/10.1016/j.juro.2016.05.090.

  26. Shin SH, Cho BS, Park SS, Cho SY, Jeon YW, Yoon JH, et al.Comparison of the modified low-dose cytarabine and etoposidewith decitabine therapy for elderly acute myeloid leukemiapatients unfit for intensive chemotherapy. Oncotarget2018; 9 (5): 5823-33. doi: 10.18632/oncotarget.23629.

  27. Garciá-Suárez J, De La Cruz J, Cedillo Á, Llamas P, Duarte R,Jiménez-Yuste V, et al. Impact of hematologic malignancyand type of cancer therapy on COVID-19 severity andmortality: Lessons from a large population-based registrystudy. J Hematol Oncol 2020; 13 (1): 1-12. https://doi.org/10.1186/s13045-020-00970-7.

  28. Jee J, Foote MB, Lumish M, Stonestrom AJ, Wills B, NarendraV, et al. Chemotherapy and COVID-19 Outcomes inPatients with Cancer. J Clin Oncol 2020; 38 (30): 3538-46.doi: 10.1200/JCO.20.01307.

  29. Vijenthira A, Gong IY, Fox TA, Booth S, Cook G, Fattizzo B,et al. Outcomes of patients with hematologic malignanciesand COVID-19: a systematic review and meta-analysis of3377 patients. Blood 2020; 136 (25): 2881-92. https://doi.org/10.1182/blood.2020008824.

  30. Girmenia C, Gentile G, Micozzi A, Petrucci L, Malaspina F,DI Prima A, et al. COVID-19 in patients with hematologicdisorders undergoing therapy: Perspective of a large referralhematology center in Rome. Acta Haematol 2020; 143(6): 574-82. https://doi.org/10.1159/000510769.




2020     |     www.medigraphic.com